Here’s the order of the upcoming Oramed/Oravax news!


Phase 2 NASH Data:
(Q3) July, August, or September
The NASH market is projected to reach $84 billion market by 2029.

Oravax:
Cohort A – (Q3) July, August, or September
Cohort B – (Q4) October, November, and December
The vaccine market is projected to reach $125 billion by 2028.

Phase 3 Oral Insulin Trials:
January 2023
Type 2 Diabetes market is projected to reach $92 billion by 2029.

84+125+92 = $301 billion in addressable markets

I would be shocked if the stock price did not claw its way back up to the $30 range or higher by New Years Eve.


Comments

Leave a Reply

Your email address will not be published. Required fields are marked *